patent.fyi
Applications  /  US 2026/0355185
United States Patent Application Publication

US 2026/0355185 A1

Published
Nov 12, 2026
Filed
Jun 26, 2026
Earliest date on the face
Mar 29, 2019
Classification
A61K 31/498
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Review of existing molecular records

What ifWhat if the evaluation used only existing molecular reports in the patient record?
Claim language“evaluating a biological sample from the patient”

A reviewer extracts the gene, variant class, and result from each finalized report. A rules table marks the record positive when it documents both an FGFR3 mutation and an FGFR3 fusion.

1.1Single mutation selection rule

What ifWhat if the molecular criterion required exactly one specified FGFR3 point mutation?
Claim language“at least two FGFR genetic alterations”

An allele-specific digital PCR assay partitions tumor DNA into droplets and uses separate fluorescent probes for the specified allele and the reference allele. The assay returns a positive result when the mutant signal exceeds the validated reporting threshold and the controls pass.

1.1Protein based eligibility testing

What ifWhat if the evaluation classified the tumor by cell-surface protein expression?
Claim language“at least two FGFR genetic alterations”

An antibody against human epidermal growth factor receptor 2 stains a fixed tumor section, and a chromogenic detection system reveals membrane staining. The report records staining intensity, completeness, and the percentage of tumor cells stained to assess eligibility for receptor-directed therapy.

1.2Antibody directed drug delivery

What ifWhat if treatment used an antibody conjugate directed at nectin-4?
Claim language“with an FGFR inhibitor”

The antibody binds nectin-4 on the surface of tumor cells, and the cells internalize the conjugate. Intracellular cleavage releases a payload that disrupts microtubules and arrests cell division.

1.2Immune checkpoint blockade

What ifWhat if treatment used an antibody that blocks an inhibitory receptor on T cells?
Claim language“with an FGFR inhibitor”

An infused antibody binds programmed cell death protein 1 on T cells and blocks its interaction with inhibitory ligands. This reduces inhibitory signaling and supports T-cell activity against tumor cells.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Paired alteration testing in veterinary oncology

A veterinary oncology workflow uses a bladder tumor biopsy from a dog with urothelial carcinoma. A targeted DNA panel detects substitutions in canine FGFR3, and a targeted RNA panel uses canine FGFR3 primers to detect expressed fusion transcripts. The treatment protocol assigns an FGFR inhibitor when both alterations are confirmed from the same biopsy.

Component substitution

Urine sediment as the test specimen

A urine sediment pellet supplies DNA and RNA for paired FGFR3 testing. Centrifugation concentrates exfoliated urothelial cells, and separate extractions from the pellet supply a DNA sequencing assay for mutations and an RNA sequencing assay for fusion junctions. The treatment workflow releases an FGFR inhibitor order for clinical review when both assays yield positive results and pass their quality controls.

Digital PCR for a defined alteration pair

Droplet digital PCR substitutes for sequencing when the assay targets a predefined FGFR3 mutation and fusion junction. One reaction uses mutation-specific and reference probes on DNA, and a second reaction uses a junction-spanning probe on reverse-transcribed RNA from the same specimen. The assay compares positive droplet counts with established thresholds and reports the pair when both signals pass their cutoffs and the controls pass. A positive paired result routes the case for FGFR inhibitor treatment.

Parameter or scale variation

Duplicate libraries for each analyte

One tumor extraction supplies two DNA aliquots and two RNA aliquots, each prepared as an independently indexed sequencing library. The DNA libraries test for FGFR3 mutations, and the RNA libraries test for FGFR3 fusion junctions. The workflow requires the same mutation in both DNA libraries and the same fusion junction in both RNA libraries before it routes the case for FGFR inhibitor treatment. A discordant pair triggers repeat testing.

Combination with existing systems

Molecular results linked to prescribing

A laboratory information system sends separate structured results for the FGFR3 mutation and fusion to an electronic prescribing system. The prescribing system matches both results by patient and specimen identifier and checks that each result is final and positive. A matching pair opens an FGFR inhibitor order set for clinician review and signature.

Automated or data-driven variant

Software verifies paired sequencing findings

A software pipeline receives indexed DNA and RNA sequencing reads and groups them by specimen identifier. It calls an FGFR3 mutation from DNA reads and detects an FGFR3 fusion from RNA reads that span a junction between FGFR3 and its partner. It checks each finding against assay-specific quality thresholds and sends passing pairs with their supporting read counts for review. A signed positive report routes the case for FGFR inhibitor treatment.

Specific version of a part

Paired tumor DNA and RNA

A fixed tumor section supplies DNA and RNA for separate sequencing libraries. Targeted DNA sequencing detects FGFR3 substitutions and short insertions or deletions, while anchored RNA amplification and sequencing identify FGFR3 fusion junctions.

Mutation probes and fusion primers

Allele-specific fluorescent probes detect predefined FGFR3 mutations in DNA extracted from tumor tissue. A separate reverse transcription PCR panel uses primer pairs that flank predefined FGFR3 fusion junctions, and the report records a call for each alteration class.

Daily oral kinase inhibition

After the report confirms both alteration classes, the patient receives a once-daily oral small-molecule FGFR inhibitor. The molecule occupies the kinase ATP-binding site and reduces receptor-mediated phosphorylation.

Intermittent oral kinase inhibition

After the report confirms an FGFR3 mutation and an FGFR3 fusion, a protocol using an intermittent oral FGFR inhibitor gives daily tablets for 14 days followed by 7 days off. Serum phosphate measurements and scheduled eye examinations inform dose interruptions and adjustments.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2012/0035171 A1
Published
Feb 9, 2012
Filed
Apr 15, 2010
Class
A61K 31/5377
Document BUS 2012/0041000 A1
Published
Feb 16, 2012
Filed
Apr 15, 2010
Class
A61K 31/437
Claim 1
Document A
Document B
1.1(a) evaluating a biological sample from the patient for the presence of at least two FGFR genetic alterations, wherein one or more of the at least two FGFR genetic alterations is an FGFR3 mutation and one or more of the at least two FGFR genetic alterations is an FGFR3 fusion; and
For example, a biological sample taken from a patient may be analysed to determine whether a condition or disease, such as cancer, that the patient is or may be suffering from is one which is characterised by a genetic abnormality or abnormal protein expression which leads to up-regulation of the levels or activity of FGFR, VEGFR and/or PDGFR or to sensitisation of a pathway to normal FGFR, VEGFR and/or PDGFR activity, or to upregulation of these growth factor signalling path
A · US 2012/0035171 A1 · ¶ 565
In addition, genetic aberrations of the FGFR3 receptor tyrosine kinase such as chromosomal translocations or point mutations resulting in ectopically expressed or deregulated, constitutively active, FGFR3 receptors have been identified and are linked to a subset of multiple myelomas, bladder and cervical carcinomas (Powers, C.
B · US 2012/0041000 A1 · ¶ 445
1.2(b) treating the patient with an FGFR inhibitor if the at least two FGFR genetic alterations are present in the sample.
Identification of an individual carrying a mutation in FGFR, VEGFR and/or PDGFR may mean that the patient would be particularly suitable for treatment with a FGFR, VEGFR and/or PDGFR inhibitor.
A · US 2012/0035171 A1 · ¶ 574
Identification of an individual carrying a mutation in FGFR. VEGFR and/or PDGFR may mean that the patient would be particularly suitable for treatment with a FGFR, VEGFR and/or PDGFR inhibitor.
B · US 2012/0041000 A1 · ¶ 450

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention relates to new bicyclic heterocyclyl derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
A · US 2012/0035171 A1 · ¶ 1
The invention relates to new bicyclic heterocyclyl derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
B · US 2012/0041000 A1 · ¶ 1
Cite aspatent.fyi, US 2026/0355185 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355185/, SHA-256 423ec6336c28c7eaa8affa531fc699be59ed2a6d16482d0f70541cd47c4b57ab
First published
Permanent addresshttps://patent.fyi/US20260355185/
Content fingerprint (SHA-256)423ec6336c28c7eaa8affa531fc699be59ed2a6d16482d0f70541cd47c4b57ab
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi